ホームページ Metabolism PARG

PARG

PARG製品

  • All (3)
  • PARG阻害剤 (3)
  • 新製品
製品コード 製品名称 製品説明 文献中Selleckの製品使用例 お客様のフィードバック
S8862 PDD00017273 PDD00017273 is a potent and selective poly (ADP ribose) glycohydrolase (PARG) inhibitor with an IC50 of 26 nM. PDD00017273 exhibits >350-fold selectivity for PARG over a panel of ion channels, enzymes and receptors, including PARP1 and ARH3.
Nucleic Acids Res, 2025, 53(4)gkaf086
Oncogene, 2025, 44(29):2515-2529
bioRxiv, 2025, 2025.07.10.663928
S4945 Ethacridine lactate Ethacridine lactate (Acrinol) is an aromatic organic compound based on acridine used as an antiseptic agent. Ethacridine lactate is also a poly(ADP-ribose) glycohydrolase (PARG) inhibitor.
E4736New COH34 COH34 is a potent and specific inhibitor of poly(ADP-ribose) glycohydrolase (PARG) with an IC50 value of 0.37 nM. It binds to the catalytic domain of PARG with Kd of 0.547 μM thereby prolonging PARylation at DNA lesions and trapping DNA repair factors and can be used in research of cancer therapies.
S8862 PDD00017273 PDD00017273 is a potent and selective poly (ADP ribose) glycohydrolase (PARG) inhibitor with an IC50 of 26 nM. PDD00017273 exhibits >350-fold selectivity for PARG over a panel of ion channels, enzymes and receptors, including PARP1 and ARH3.
Nucleic Acids Res, 2025, 53(4)gkaf086
Oncogene, 2025, 44(29):2515-2529
bioRxiv, 2025, 2025.07.10.663928
S4945 Ethacridine lactate Ethacridine lactate (Acrinol) is an aromatic organic compound based on acridine used as an antiseptic agent. Ethacridine lactate is also a poly(ADP-ribose) glycohydrolase (PARG) inhibitor.
E4736New COH34 COH34 is a potent and specific inhibitor of poly(ADP-ribose) glycohydrolase (PARG) with an IC50 value of 0.37 nM. It binds to the catalytic domain of PARG with Kd of 0.547 μM thereby prolonging PARylation at DNA lesions and trapping DNA repair factors and can be used in research of cancer therapies.
E4736New COH34 COH34 is a potent and specific inhibitor of poly(ADP-ribose) glycohydrolase (PARG) with an IC50 value of 0.37 nM. It binds to the catalytic domain of PARG with Kd of 0.547 μM thereby prolonging PARylation at DNA lesions and trapping DNA repair factors and can be used in research of cancer therapies.
united states